Why Health Care's Seasonal Tailwind Looks Especially Compelling This YearZacks Investment Research • 06/05/26
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?Zacks Investment Research • 06/05/26
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?Zacks Investment Research • 06/05/26
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease TherapiesBenzinga • 06/04/26
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 SuccessThe Motley Fool • 06/04/26
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even BetterThe Motley Fool • 06/03/26
Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry24/7 Wall Street • 06/03/26
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn'tThe Motley Fool • 06/03/26
5 Stocks Set to Cash in on The Next 90-Million Customer Industry. (It's Not AI)24/7 Wall Street • 06/03/26
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugsReuters • 06/03/26
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areasCNBC • 06/03/26
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch OutThe Motley Fool • 06/03/26